Adenoviruses in Fecal Samples from Asymptomatic Rhesus Macaques, United States

Isolates contained fiber genes similar to those of adenovirus strains that cause infectious diarrhea in humans

Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE

Introduction: The current mainstay of the treatment of thrombotic antiphospholipid syndrome (APS) is long-term anticoagulation with vitamin K antagonists (VKAs) such as warfarin. Non-VKA oral anticoagulants (NOACs), which include rivaroxaban, have been shown to be effective and safe compared with warfarin for the treatment of venous thromboembolism (VTE) in major phase III prospective, randomized controlled trials (RCTs), but the results may not be directly generalizable to patients with APS. Aims: The primary aim is to demonstrate, in patients with APS and previous VTE, with or without systemic lupus erythematosus (SLE), that the intensity of anticoagulation achieved with rivaroxaban is not inferior to that of warfarin. Secondary aims are to compare rates of recurrent thrombosis, bleeding and the quality of life in patients on rivaroxaban with those on warfarin. Methods: Rivaroxaban in antiphospholipid syndrome (RAPS) is a phase II/III prospective non-inferiority RCT in which eligible patients with APS, with or without SLE, who are on warfarin, target international normalized ratio (INR) 2.5 for previous VTE, will be randomized either to continue warfarin (standard of care) or to switch to rivaroxaban. Intensity of anticoagulation will be assessed using thrombin generation (TG) testing, with the primary outcome the percentage change in endogenous thrombin potential (ETP) from randomization to day 42. Other TG parameters, markers of in vivo coagulation activation, prothrombin fragment 1.2, thrombin antithrombin complex and D-dimer, will also be assessed. Discussion: If RAPS demonstrates i) that the anticoagulant effect of rivaroxaban is not inferior to that of warfarin and ii) the absence of any adverse effects that cause concern with regard to the use of rivaroxaban, this would provide sufficient supporting evidence to make rivaroxaban a standard of care for the treatment of APS patients with previous VTE, requiring a target INR of 2.5

SPECIFICATIONS OF A PROTOTYPE SOFTWARE SYSTEM FOR DEVELOPING VARIABLE-RATE TREATMENT PRESCRIPTIONS FOR USE IN PRECISION AGRICULTURE

This paper discusses the process of developing variable-rate treatment prescriptions and gives specifications for a prototype software system for implementing that process. The process is based on statistical analysis of data from embedded field trials, and incorporates producer preferences in determining a treatment prescription. The system can be used by researchers in agricultural research stations for developing prescriptions for commercial agricultural producers. The specifications provided are general enough to be implemented using a variety of statistical and database packages that are available to researchers. In addition to these specifications we provide online access to source code for implementing the system in SAS. We use this system to develop treatment prescriptions for a commercial cotton farming operation in northeast Louisiana. The prescriptions are based on data from a precision agriculture experiment conducted in 2006. The objective of that study was to compare the effects of five nitrogen rates on cotton lint yield across several soil types for the purpose of developing a variable-rate nitrogen treatment prescription for future use on that farm. Several possible producer preferences were incorporated with the results of the field trial to produce optional treatment prescriptions for the producer

PRNP Haplotype Associated with Classical BSE Incidence in European Holstein Cattle

Background: Classical bovine spongiform encephalopathy (BSE) is an acquired prion disease of cattle. The bovine prion gene (PRNP) contains regions of both high and low linkage disequilibrium (LD) that appear to be conserved across Bos taurus populations. The region of high LD, which spans the promoter and part of intron 2, contains polymorphic loci that have been associated with classical BSE status. However, the complex genetic architecture of PRNP has not been systematically tested for an association with classical BSE. Methodology/Principal Findings: In this study, haplotype tagging single nucleotide polymorphisms (htSNPs) within PRNP were used to test for association between PRNP haplotypes and BSE disease. A combination of Illumina goldengate assay, sequencing and PCR amplification was used to genotype 18 htSNPs and 2 indels in 95 BSE case and 134 control animals. A haplotype within the region of high LD was found to be associated with BSE unaffected animals (p-value = 0.000114). Conclusion/Significance: A PRNP haplotype association with classical BSE incidence has been identified. This result suggests that a genetic determinant in or near PRNP may influence classical BSE incidence in cattle

Ovine reference materials and assays for prion genetic testing

<p>Abstract</p> <p>Background</p> <p>Genetic predisposition to scrapie in sheep is associated with several variations in the peptide sequence of the prion protein gene (<it>PRNP</it>). DNA-based tests for scoring <it>PRNP </it>codons are essential tools for eradicating scrapie and for evaluating rare alleles for increased resistance to disease. In addition to those associated with scrapie, there are dozens more <it>PRNP </it>polymorphisms that may occur in various flocks. If not accounted for, these sites may cause base-pair mismatching with oligonucleotides used in DNA testing. Thus, the fidelity of scrapie genetic testing is enhanced by knowing the position and frequency of <it>PRNP </it>polymorphisms in targeted flocks.</p> <p>Results</p> <p>An adaptive DNA sequencing strategy was developed to determine the 771 bp <it>PRNP </it>coding sequence for any sheep and thereby produce a consensus sequence for targeted flocks. The strategy initially accounted for 43 known polymorphisms and facilitates the detection of unknown polymorphisms through an overlapping amplicon design. The strategy was applied to 953 sheep DNAs from multiple breeds in U.S. populations. The samples included two sets of reference sheep: one set for standardizing <it>PRNP </it>genetic testing and another set for discovering polymorphisms, estimating allele frequencies, and determining haplotype phase. DNA sequencing revealed 16 previously unreported polymorphisms, including a L237P variant on the F₁₄₁haplotype. Two mass spectrometry multiplex assays were developed to score five codons of interest in U.S. sheep: 112, 136, 141, 154, and 171. Reference tissues, DNA, trace files, and genotypes from this project are publicly available for use without restriction.</p> <p>Conclusion</p> <p>Identifying ovine <it>PRNP </it>polymorphisms in targeted flocks is critical for designing efficient scrapie genetic testing systems. Together with reference DNA panels, this information facilitates training, certification, and development of new tests and knowledge that may expedite the eradication of sheep scrapie.</p

\u27USU-Apogee\u27 Wheat - Registration

\u27USU-Apogee\u27 is a full-dwarf hard red spring wheat (Triticum aestivum L.) (NSSL Reg. no. 331390.01; PI 592742) cultivar developed for high yields in controlled environments. USU-Apogee was developed by the Utah Agricultural Experiment Station in cooperation with the National Aeronautics and Space Administration and released in April 1996. NASA is interested in improved food crops for bioregenerative life support systems in space. Apogee is the point in an orbit farthest from the earth. USU-Apogee is a shorter, higher yielding alternative to \u27Yecora Rojo\u27 and \u27Veery-10\u27, the short field cultivars previously selected for use in controlled environments (Bugbee and Salisbury, 1988). USU-Apogee (45-50 cm tall, depending on temperature) is 10 to 15 cm shorter than Yecora Rojo and 2 to 5 cm shorter than Veery-10. USU-Apogee was also selected for resistance to the calcium-induced leaf tip necrosis that occurs in controlled-environments

Changes in the Carbon and Energy Balance of the Sagebrush Steppe Ecosystem of the Pacific Northwest - White Paper

We propose a multi-agency study to understand the impacts of land-use change on the carbon and energy balance of the Pacific Northwest. By integrating data for the carbon and energy fluxes across different scales within each land-use type, we will develop more accurate input parameters for the regional climate models. The product of this study will address two priorities recommended by the National Academy of Sciences; 1) reduce uncertainties in climate change projections and 2) provide a more definitive evaluation of long-term changes